Clinical trials: irinotecan hydrochloride
Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
Non-commercial, prospective, randomized, multicenter, national, phase II, open-label comparative clinical trial. The patients will be randomized in a 1: 1 ratio in two arms: Control arm.
- Trial name
- LIVERPEARL (NCT04595266)
- Testing
- FOLFOX regimen, Anti-EGFR or Bevacizumab, LIVERPEARLS-Irinotecan
- Where
- 8 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Brain and Central Nervous System Tumors
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005951
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Sponsor
- Duke University
Pancreas Cancer
Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
To determine recommended phase 2 dose and to evaluate the safety of vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed first-line gemcitabine and…
- Trial name
- NCT04258072
- Testing
- Vactosertib
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Samsung Medical Center
Breast Neoplasms, Breast Cancer
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early…
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma
- Trial name
- I-SPY (NCT01042379)
- Testing
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin
- Where
- 42 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Colorectal Cancer
OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer
This single arm study will assess progression-free survival, feasibility of use and safety of Avastin in combination with 5-FU/FA, oxaliplatin and irinotecan (FOLFOXIRI) as first line treatment in patients with metastatic…
- Trial name
- NCT00940303
- Testing
- 5-FU, bevacizumab [Avastin], irinotecan
- Where
- 17 sites in Germany
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Biliary Tract Cancer
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
FOLFIRI as a salvage treatment in metastatic biliary tract cancer (BTC) patients who failed gemcitabine containing chemotherapy
- Trial name
- NCT03110510
- Testing
- Fluorouracil, Irinotecan Hydrochloride, leucovorin calcium
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Rectal Carcinoma
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical…
- Trial name
- NCT00682786
- Testing
- 5FU, Radiation, Surgery of resectable lesions
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Washington University School of Medicine
Esophageal Cancer, Gastric Cancer
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
The main purpose of this study is to see whether the combination of selinexor (KPT-330) and irinotecan can help people with esophageal or stomach cancer.
- Trial name
- NCT02283359
- Testing
- Selinexor, Irinotecan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Solid Tumor, Metastatic Solid Tumor
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
- Trial name
- NCT06974110
- Testing
- MOMA-341, Irinotecan, Immunotherapy
- Where
- 15 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- MOMA Therapeutics
Adenocarcinoma of the Stomach, Adenocarcinoma of the Gastroesophageal Junction
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach
Open label, randomised, multicenter, superiority study for efficacy. Patients with histologically proven adenocarcinoma of the stomach or gastroesophageal junction without gross or microscopic evidence of residual disease after…
- Trial name
- ITACA-S (NCT01640782)
- Testing
- Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin, Leucovorin, 5-Fluorouracil
- Where
- 101 sites in Italy
- Volunteers
- 1,100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Gastro-Intestinal Cancer
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of…
- Trial name
- NCT05332002
- Testing
- Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Rutgers, The State University of New Jersey
Colorectal Cancer
Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as irinotecan and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00303745
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- 23 sites in France
- Volunteers
- 78 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Stomach Neoplasm
ILF With/Without Cisplatin for Advanced Gastric Cancer
To compare the combination of irinotecan, leucovorin and 5-FU (ILF) with ILF plus cisplatin (PILF) as first-line chemotherapy in patients with measurable metastatic gastric cancer.
- Trial name
- NCT00320294
- Testing
- irinotecan, cisplatin
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Gachon University Gil Medical Center
Diarrhea, Drug/Agent Toxicity by Tissue/Organ
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
- Trial name
- NCT00093353
- Testing
- cefixime, irinotecan hydrochloride, temozolomide
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Refractory Solid Tumors in Children
A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
This phase I study is designed to determine the maximum tolerated dose of Irinotecan given intravenous for 5 days every 3 weeks in combination with fixed doses of Vincristine, Temozolomide and Bevacizumab (VIT-B) in patients with…
- Trial name
- VIT-B (NCT00993044)
- Testing
- Irinotecan, Vincristine, Temozolomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Los Angeles
Metastatic Colorectal Cancer
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).
- Trial name
- QUATTRO-II (NCT04097444)
- Testing
- Bevacizumab, 5-fluorouracil, Leucovorin calcium
- Where
- Japan
- Volunteers
- 112 people
- Sponsor
- Chugai Pharmaceutical
Non Small Cell Lung Cancer
Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV
This trial will compare the efficacy of irinotecan/cisplatin and pemetrexed/cisplatin in the second-line treatment of patients with stage IIIB/IV NSCLC
- Trial name
- NCT00614965
- Testing
- Irinotecan, Cisplatin, Pemetrexed
- Where
- 2 sites in Greece
- Volunteers
- 124 people
- Sponsor
- Hellenic Oncology Research Group
Esophageal Cancer, Gastric Cancer
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the…
- Conditions
- Esophageal Cancer, Gastric Cancer, GE Junction Cancer
- Trial name
- NCT00165464
- Testing
- Taxotere, Cisplatin, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Colorectal Cancer
Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma
Primary objective:To assess the efficacy, defined as overall survival, of sequential versus combination chemotherapy for advanced colorectal cancer (CRC). Methodology Open, randomised multicenter phase III study.
- Trial name
- NCT00312000
- Testing
- capecitabine-irinotecan, capecitabine+irinotecan (1st line)
- Volunteers
- 820 people
- Sponsor
- Dutch Colorectal Cancer Group
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC